Mendeleev Commun., 2006, 16(1), 52–54
cyclization of compound 3b and its analogues is favoured by
adducts with barbituric acids. It seems evident that the con-
siderably higher affinity of 5-arylidenebarbiturates derived from
aldehydes 2b–e towards cyclization is due to an increase in the
electron density at the alkylamino group and to the stabilization
of cationic segment in the zwitter-ionic intermediate.
In conclusion, the study of T-reactions of barbituric acid deri-
vatives clarified the mechanism of hydrogen migration in the
tert-amino effect and enabled a simple method for the prepara-
tion of new heterocyclic systems containing the pyrimidine-5-
spiro-3'-quinoline skeleton.
the stabilization of zwitter-ionic system 6 through the effective
delocalization of the negative charge over the atoms of the
β-dicarbonyl pentad. Taking all these aspects into consideration,
the mechanism of hydrogen migration in 5-arylidenebarbiturate
3b may be described as the intramolecular uptake of a hydrid
ion by a Lewis acceptor.
A high rate of the tert-amino effect cyclization was proved by
the examination of the reactivity of 2-dimethylamino-4-methyl-
benzaldehyde 2b† in these reactions. The condensation of acid
1a with aldehyde 2b afforded spirocyclic derivative 4c¶¶ without
stopping at the Knövenagel stage, even at a room temperature.
The formation of the Knövenagel intermediate manifests itself
only by appearance of a deep red colour of the reaction mixture.
Kinetic measurements showed that the rate of this two-step pro-
cess was limited by the first stage. We have restricted ourselves
by estimation that the rate of the rearrangement of 5-(2-dimethyl-
amino-4-methylbenzylidene)barbiturate at 20 °C in DMSO is
three orders of magnitude (or more) higher than that in the case
of its 4-nitro analogue 3a.
1,3-Dimethylbarbituric 1b and 1,3-diphenylbarbituric 1c acids,
as well as their 2-thio analogues 1d,e, interact with aldehyde 2b
to afford spirocyclic products 4d–g.¶¶ 2-Dimethylamino-4,5-di-
methylbenzaldehyde 2c† was found to react similarly to its
analogue 2b: the condensation of 2c with acid 1a yielded spiro-
cyclic product 4h.¶¶ The interaction of 2-diethylamino-4-nitro
2d or 2-benzylmethylamino-4-nitro 2e benzaldehydes† with acid
1a proceeds to give 5-spirobarbiturates 4i,j.¶¶
References
1
2
3
J. T. Bojarski, J. L. Mokrosz, H. J. Barton and M. H. Paluchowska,
Adv. Heterocycl. Chem., 1985, 38, 229.
K. A. Krasnov, in Izbrannye metody sinteza i modifikatsii geterotsiklov
(Selected Methods for Synthesis and Modification of Heterocycles),
ed. V. G. Kartsev, IBS Press, Moscow, 2002, vol. 1, p. 281 (in Russian).
O. Meth-Cohn, Adv. Heterocycl. Chem., 1996, 65, 1.
A. Schwartz, G. Beke, Z. Kovari, Z. Bocskey, O. Farkas and P. Matyus,
Theochem, 2000, 528, 49.
4
5
6
7
E. V. D’yachenko, T. V. Glukhareva, E. F. Nikolaenko, A. V. Tkachev
and Yu. Yu. Morzherin, Izv. Akad. Nauk, Ser. Khim., 2004, 1191 (Russ.
Chem. Bull., Int. Ed., 2004, 53, 1240).
8
9
K. A. Krasnov, V. G. Kartsev and V. N. Khrustalev, Izv. Akad. Nauk,
Ser. Khim., 2002, 1418 (Russ. Chem. Bull., Int. Ed., 2002, 51, 1540).
These data show that aldehydes 2b–e, in contrast to 2-dimethyl-
amino-4-nitrobenzaldehyde 2a, do not form stable Knövenagel
12 G. D. Desiraju and T. Steiner, The Weak Hydrogen Bond in Structural
Chemistry and Biology, Oxford Science Publications, Oxford, 1999.
15 M. Nishio, Cryst. Eng. Comm., 2004, 6, 130.
¶¶ General procedure. An ethanolic solution of aldehyde 2b–e (10 mmol)
was added to a stirred solution of barbituric or 2-thiobarbituric acid
derivative 1a–e (10 mmol) in aqueous EtOH (70%) at 60–70 °C, and
the mixture was heated at 60 °C for 10–15 min. Then the mixture was
cooled and the precipitate was purified by crystallization from EtOH.
2,4,6-Trioxoperhydropyrimidine-5-spiro-3'-(1',6'-dimethyl-1',2',3',4'-
tetrahydroquinoline) 4c. Yield 91%, colourless crystals, mp 286–287 °C.
1H NMR ([2H6]DMSO) d: 2.21 (s, 3H, ArMe), 2.87 (s, 3H, NMe), 3.05 (s,
2H, ArCH2), 3.35 (s, 2H, NCH2), 6.50 (d, 1H, ArH, J 7.3 Hz), 6.80 (s,
1H, ArH), 6.81 (d, 1H, ArH, J 7.3 Hz), 11.12 (s, 2H, 2NH). 13C NMR
([2H6]DMSO) d: 19.97 (MeAr), 31.06 (NMe), 38.67 (CH2Ar), 50.09
(CCO), 56.38 (NCH2), 111.47 (CH), 121.52 (C), 125.41 (C), 126.81
(CH), 128.58 (CH), 143.47 (CaromN), 171.13 [C(4)O, C(6)O], 150.36
[C(2)O]. MS, m/z (%): 273 (100) [M]+, 258 (43), 201 (25), 186 (14).
Found (%): C, 61.41; H, 5.66; N, 15.29. Calc. for C14H15N3O3 (%): C,
61.53; H, 5.53; N, 15.38.
16 G. R. Desiraju, Chem. Commun., 2005, 2995.
Received: 14th July 2005; Com. 05/2549
1,3-Diphenyl-2-thioxo-4,6-dioxoperhydropyrimidine-5-spiro-3'-(1',6'-
1,3-Dimethyl-2,4,6-trioxoperhydropyrimidine-5-spiro-3'-(1',6'-dimethyl-
dimethyl-1',2',3',4'-tetrahydroquinoline) 4g. Yield 84%, colourless crys-
tals, mp 241–242 °C. H NMR (CDCl3) d: 2.25 (s, 3H, ArMe), 3.05 (s,
1
1',2',3',4'-tetrahydroquinoline) 4d. Yield 79%, colourless crystals, mp 151–
1
152 °C. H NMR (CDCl3) d: 6.92 (d, 1H, ArH, J 7.3 Hz), 6.85 (s, 1H,
3H, NMe), 3.46 (s, 2H, ArCH2), 3.74 (s, 2H, NCH2), 6.60 (d, 1H, ArH,
J 7.2 Hz), 6.91 (d, 1H, ArH, J 7.2 Hz), 6.96 (s, 1H, ArH), 7.16 (m, 4H,
2Ph), 7.41–7.48 (m, 6H, 2Ph). Found (%): C, 70.45; H, 5.48; N, 9.33;
S, 7.14. Calc. for C26H23N3O2S (%): C, 70.72; H, 5.25; N, 9.52; S, 7.26.
1,3-Dimethyl-2,4,6-trioxoperhydropyrimidine-5-spiro-3'-(1',5',6'-tri-
methyl-1',2',3',4'-tetrahydroquinoline) 4h. Yield 76%, colourless crys-
tals, mp 143–144 °C. 1H NMR ([2H6]DMSO) d: 2.08 (s, 3H, ArMe),
2.12 (s, 3H, ArMe), 2.85 (s, 3H, NMe), 3.10 (s, 2H, CCH2), 3.34 (s, 2H,
NCH2), 6.40 (s, 1H, ArH), 6.72 (s, 1H, ArH), 11.06 (s, 2H, 2NH).
13C NMR ([2H6]DMSO) d: 18.55 (MeAr), 19.84 (MeAr), 32.21 (MeNAr),
38.87 (CH2Ar), 50.32 (CCO), 56.90 (CH2N), 112.13 (CH), 118.68 (C),
126.51 (C), 130.79 (CH), 135.92 (C), 143.15 (CaromN), 150.44 [C(2)O],
170.94 [C(4)O, C(6)O]. Found (%): C, 64.91; H, 6.86; N, 13.22. Calc.
for C17H21N3O3 (%): C, 64.74; H, 6.71; N, 13.32.
2,4,6-Trioxoperhydropyrimidine-5-spiro-3'-(1'-ethyl-2'-methyl-6'-nitro-
1',2',3',4'-tetrahydroquinoline) 4i. Yield 70%, yellow crystals, mp 244–
245 °C. 1H NMR ([2H6]DMSO) d: 1.02 (d, 3H, CHMe, J 6.6 Hz), 1.11 (t,
3H, CH2Me, J 7.5 Hz), 2.88 and 3.49 (AB-d, 2H, ArCH2, J 17.5 Hz), 3.33
and 3.60 (AB-m, 2H, NCH2), 4.01 (q, 1H, NCH, J 6.6 Hz), 6.68 (d, 1H,
ArH, J 9.3 Hz), 7.89 (d, 1H, ArH, J 9.3 Hz), 7.94 (s, 1H, ArH), 11.08 (s,
1H, NH), 11.25 (s, 1H, NH). Found (%): C, 54.57; H, 4.97; N, 16.79.
Calc. for C15H16N4O5 (%): C, 54.22; H, 4.85; N, 16.86.
ArH), 6.59 (d, 1H, ArH, J 7.3 Hz), 3.40 (s, 2H, NCH2), 3.30 (s, 6H,
2NMe), 3.22 (s, 2H, ArCH2), 2.92 (s, 3H, NMe), 2.25 (s, 3H, ArMe).
13C NMR (CDCl3) d: 169.53 [C(4)O, C(6)O], 151.36 [C(2)O], 142.74
(CaromN), 128.98 (CH), 127.84 (CH), 127.32 (C), 120.52 (C), 112.04
(CH), 58.11 (CH2N) 50.95 (CCO), 39.47 (CH2Ar), 32.82 (MeNAr),
29.05 (2MeN), 20.36 (MeAr). Found (%): C, 63.59; H, 6.54; N, 13.80.
Calc. for C16H19N3O3 (%): C, 63.77; H, 6.36; N, 13.94.
1,3-Diphenyl-2,4,6-trioxoperhydropyrimidine-5-spiro-3'-(1',6'-dimethyl-
1',2',3',4'-tetrahydroquinoline) 4e. Yield 82%, colourless crystals,
1
mp 253–254 C. H NMR (CDCl3) d: 2.22 (s, 3H, ArMe), 2.97 (s, 3H,
NMe), 3.29 (s, 2H, ArCH2), 3.73 (s, 2H, NCH2), 6.53 (d, 1H, ArH,
J 8.0 Hz), 6.80 (d, 1H, ArH, J 8.0 Hz), 6.89 (s, 1H, ArH), 7.29–7.47 (m,
10H, 2Ph). 13C NMR (CDCl3) d: 20.32 (MeAr), 32.36 (MeN), 39.53
(CH2Ar), 52.37 (CCO), 58.23 (CH2N), 112.14 (CH), 120.26 (C), 127.56
(CH), 127.90 (CH), 128.20 (C), 128.28 (4CH), 129.02 (2CH), 129.30
(4CH), 134.37 (2C), 142.64 (CaromN), 150.63 [C(2)O], 168.94 [C(4)O,
C(6)O]. Found (%): C, 72.98; H, 5.73; N, 9.56. Calc. for C26H23N3O3
(%): C, 73.40; H, 5.45; N, 9.88.
1,3-Dimethyl-2-thioxo-4,6-dioxoperhydropyrimidine-5-spiro-3'-(1',6'-
dimethyl-1',2',3',4'-tetrahydroquinoline) 4f. Yield 75%, colourless crystals,
1
mp 192–193 °C. H NMR (CDCl3) d: 2.26 (s, 3H, ArMe), 2.92 (s, 3H,
ArNMe), 3.29 (s, 2H, ArCH2), 3.42 (s, 2H, NCH2), 3.66 (s, 6H, 2NMe),
6.62 (d, 1H, ArH, J 8.2 Hz), 6.89 (s, 1H, ArH), 6.93 (d, 1H, ArH,
J 8.2 Hz). 13C NMR (CDCl3) d: 20.39 (MeAr), 32.22 (MeNAr), 35.95
(2MeN), 39.50 (CH2Ar), 52.11 (CCO), 57.74 (CH2N), 112.14 (CH),
120.42 (C), 127.50 (C), 127.88 (CH), 129.07 (CH), 142.68 (CaromN),
168.04 (2CO), 180.60 (CS). Found (%): C, 54.27; H, 4.99; N, 16.84; S,
10.06. Calc. for C16H19N3O2S (%): C, 54.22; H, 4.85; N, 16.86; S, 10.10.
2,4,6-Trioxoperhydropyrimidine-5-spiro-3'-(1'-methyl-2'-phenyl-6'-nitro-
1',2',3',4'-tetrahydroquinoline) 4j. Yield 87%, yellow crystals, mp 224–
1
225 °C. H NMR ([2H6]DMSO) d: 2.90 (s, 3H, NMe), 3.36 and 3.13
(AB-d, 2H, NCH2, J 17.5 Hz), 5.13 (s, 1H, NCH), 6.65 (m, 1H, ArH),
7.01 (m, 2H, Ph), 7.24 (m, 3H, Ph), 7.92 (d, 1H, ArH, J 5.0 Hz), 8.04
(m, 1H, ArH), 11.12 (s, 2H, 2NH). Found (%): C, 59.88; H, 4.30; N,
14.79. Calc. for C19H16N4O5 (%): C, 60.00; H, 4.24; N, 14.73.
54 Mendeleev Commun. 2006